Patients in England who have prostate cancer will now be given early access to a drug that can delay the need for chemotherapy. Abiraterone has now been deemed affordable by the National Institute for Health and Care Excellence (NICE). Previously, they had said the treatment wasn’t cost effective for the NHS until prostate cancer reaches an […]